MyHealthChecked PLC (FORF) AI Stock Analysis

• Market Cap: £3.86M
• Dividend Yield: N/A
• Average Volume (3M): 35.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 14
• Sector: Financial
• Sector Strength: 70
• Industry: Shell Companies
• EPS (TTM): N/A
• Shares Outstanding: 51,600,826
• 10 Day Avg. Volume: 35,100
• 30 Day Avg. Volume: 35,181
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -2.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: 7.50 p
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is driven primarily by weak financial performance (steep revenue decline, negative gross profit, and cash burn in 2024), with only partial support from a low-debt balance sheet. Technicals add pressure with a clear downtrend and negative MACD, while valuation is difficult to justify due to negative earnings and no dividend support.

MyHealthChecked PLC Business Overview & Revenue Model

Company Description

Fortis Frontier PLC develops, distributes, and commercializes at-home healthcare and wellness tests in the United Kingdom. The company offers general health and energy profile blood test, bowel health rapid test, and stomach ulcer rapid test; nutritional health tests, such as intolerances and sensitivities DNA tests, vitamins and minerals DNA and profile blood tests, iron deficiency rapid test, and vitamin D rapid test; and weight management tests that includes weight management DNA and blood tests, glucose management DNA tests, and thyroid profile blood test and stimulating hormone rapid test. It also provides cardiovascular health tests, such as heart profile blood and heart profile test; women's health tests comprising female sexual health test, polycystic ovary syndrome blood test, and menopause profile blood test; and men's health products, including erectile dysfunction blood test, male sexual health test, and sperm concentration rapid test. The company was formerly known as MyHealthChecked PLC and changed its name to Fortis Frontier PLC in November 2025. Fortis Frontier PLC was incorporated in 2008 and is based in Cardiff, the United Kingdom.

How the Company Makes Money

MyHealthChecked makes money by selling diagnostic testing and related laboratory services. Key revenue streams include: (1) test kit sales (including at-home/self-collection or point-of-care formats) where revenue is generated per unit sold; (2) laboratory testing services, where revenue is earned for processing samples and delivering results/interpretation as a service (often tied to each test performed); and (3) contract or program-based supply and testing arrangements with third parties (e.g., employers, retailers, healthcare organizations, or public-sector bodies) where revenue may be generated through bulk orders, service-level agreements, or per-test pricing. Any specific material partnerships, customer concentration, pricing structure, or the relative contribution of each revenue stream is null.

MyHealthChecked PLC Financial Statement Overview

Summary

Overall fundamentals are weak: the income statement shows a sharp revenue drop (~62% YoY in 2024) and a swing into large losses with negative gross profit, and cash flow deteriorated to materially negative operating cash flow and free cash flow in 2024. The main offset is a comparatively solid balance sheet with minimal/zero debt, which reduces near-term financial risk but does not fix the operating decline.

Income Statement

Performance has deteriorated sharply: revenue fell to 3.6m in 2024 (down ~62% YoY) after a prior step-down in 2023, and profitability swung from a solid profit in 2021–2022 to losses in 2023 and a much larger loss in 2024. Margins compressed materially, with 2024 showing negative gross profit and deep operating losses, indicating significant pricing pressure, under-absorption of costs, or mix/volume issues. Strength: the company has shown it can be profitable (2021–2022), but the recent trajectory is clearly negative and volatile.

Balance Sheet

The balance sheet is a relative strength: debt is minimal to zero across the period (including 0 debt in 2024), keeping financial leverage low and reducing refinancing risk. Equity remains meaningful (6.98m in 2024), though it has declined from 2022–2023 levels, consistent with recent losses. Return on equity turned negative in 2023 and worsened in 2024, signaling weak capital efficiency and potential ongoing equity erosion if losses persist.

Cash Flow

Cash generation weakened materially: operating cash flow was positive in 2021–2023 but turned sharply negative in 2024 (-2.16m), and free cash flow also moved deeper into the red (-2.26m). The cash flow profile has become less reliable, and the large negative free cash flow growth in 2024 highlights a worsening funding gap. A partial offset is that free cash flow and net income moved in the same direction (both negative in 2024), but the business is currently consuming cash rather than funding itself.

Breakdown	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.61M	10.98M	22.31M	16.38M	50.00K
Gross Profit	-194.00K	2.05M	4.79M	5.13M	-640.30K
EBITDA	-1.53M	30.00K	1.74M	2.16M	-3.60M
Net Income	-1.79M	-159.00K	1.52M	2.00M	-3.76M
Balance Sheet
Total Assets	8.80M	13.34M	11.43M	11.67M	1.34M
Cash, Cash Equivalents and Short-Term Investments	5.47M	7.75M	7.61M	6.39M	465.67K
Total Debt	0.00	26.00K	53.00K	0.00	109.26K
Total Liabilities	1.83M	4.64M	2.58M	4.55M	806.08K
Stockholders Equity	6.97M	8.70M	8.85M	7.11M	529.38K
Cash Flow
Free Cash Flow	-2.26M	157.00K	1.27M	2.77M	-2.19M
Operating Cash Flow	-2.16M	724.00K	1.61M	3.01M	-2.16M
Investing Cash Flow	-93.00K	-531.00K	-338.00K	-299.00K	-38.00K
Financing Cash Flow	-23.00K	-52.00K	-47.00K	3.21M	1.96M

MyHealthChecked PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
EKF	67 Neutral	£105.28M	15.58	8.50%	―	-1.43%	28.57%
RUA	59 Neutral	£8.53M	3.60	0.08%	―	87.72%	―
IHC	52 Neutral	£20.62M	-18.39	-69.35%	―	31.78%	10.27%
CREO	48 Neutral	£48.47M	0.83	32.72%	―	―	―
SUN	43 Neutral	£4.20M	77.73	-16.78%	―	-4.98%	-114.29%
FORF	42 Neutral	£3.86M	-1.03	-34.26%	―	―	―

MyHealthChecked PLC Corporate Events

Fortis Frontier Buys Back Shares and Appoints New Broker as Cash Shell

Fortis Frontier PLC, an AIM-quoted cash shell that formerly operated as diagnostics group MyHealthChecked PLC, has no active trading business following the sale of its subsidiary Concepta Diagnostics and is focused on identifying new strategic opportunities. The board is reviewing options to leverage its listed status and capital base to pursue transactions that could restore operating activities and drive returns for shareholders.

The company has repurchased 85,000 shares, about 0.16% of its capital, at 8p per share and intends to cancel them, reducing the issued share count to 51,600,827 and marginally increasing remaining investors’ proportional holdings. Fortis Frontier has also appointed Singer Capital Markets as its corporate broker, following the transfer of the Dowgate Capital team, while retaining SPARK Advisory Partners as nominated adviser, ensuring continuity of market support during its strategic review phase.

The most recent analyst rating on (GB:FORF) stock is a Sell with a £8.00 price target. To see the full list of analyst forecasts on MyHealthChecked PLC stock, see the GB:FORF Stock Forecast page.

Fortis Frontier Tightens Share Base Ahead of Strategic Pivot

Fortis Frontier repurchased 250,000 shares at 8p each on 3 February 2026 under its AGM authority, with the shares to be cancelled, reducing total voting rights to 51,685,827 once treasury shares are extinguished, a move that narrows the capital base while the board evaluates strategic options for redeploying the shell’s cash. The transaction signals continued capital discipline as the company seeks to optimise its share structure ahead of any potential acquisition or reverse takeover, offering investors clarity on the voting denominator and reinforcing management’s intent to preserve flexibility for future deals.

The most recent analyst rating on (GB:FORF) stock is a Sell with a £8.00 price target. To see the full list of analyst forecasts on MyHealthChecked PLC stock, see the GB:FORF Stock Forecast page.

Fortis Frontier Cuts Share Count with Small Buyback as Cash Shell Weighs Next Move

Fortis Frontier PLC, an AIM-quoted cash shell, has bought back 100,000 ordinary shares at 8 pence per share for cancellation, alongside cancelling a further 105 treasury shares arising from a previous share consolidation. Once these transactions settle and the treasury shares are cancelled, the company’s issued share capital will stand at 51,935,827 ordinary shares, a new figure that investors will use to calculate their voting rights and disclosure obligations under FCA rules, marking a modest capital reduction as the board continues to assess strategic options to enhance shareholder value.

The most recent analyst rating on (GB:FORF) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on MyHealthChecked PLC stock, see the GB:FORF Stock Forecast page.

Fortis Frontier Chairman Increases Stake and Surrenders Share Options

Fortis Frontier PLC announced that Executive Chairman Adam Reynolds has purchased 50,000 ordinary shares at 8.5 pence per share, increasing his total direct and indirect holding to 750,886 shares, or approximately 1.44% of the company’s issued share capital. Reynolds has simultaneously surrendered options over 66,667 ordinary shares with a significantly higher exercise price, a move that may be interpreted as a vote of confidence in the company’s current valuation and strategic direction as the newly rebranded cash shell continues to explore routes to enhance shareholder value following the sale of its former operating subsidiary.

The most recent analyst rating on (GB:FORF) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on MyHealthChecked PLC stock, see the GB:FORF Stock Forecast page.